David Feltquate

Global Head, Hematology Disease Unit at Novartis

David Feltquate is a prominent figure in the pharmaceutical industry with extensive experience in oncology and hematology. Here's a brief overview of his career:

Career Highlights

Current Position: David Feltquate currently serves as the Chief Medical Officer at iTeos Therapeutics.2 3 He started this position in June 2021.4

Previous Role at Novartis: Prior to joining iTeos Therapeutics, Feltquate held the position of Global Head of Hematology Development at Novartis.1 2 In this role, he was also the Chair of the Precision Medicine Leadership Team.1 2

Experience at Bristol-Myers Squibb (BMS): Before his time at Novartis, Feltquate had a significant tenure at Bristol-Myers Squibb, where he held several leadership positions:

Head of Oncology Early Clinical Development
Development Leader for Ipilimumab/Nivolumab Life Cycle Management
Nivolumab Clinical Head, where he was responsible for developing the first PD1 inhibitor from proof of concept through initial registrations in non-small cell lung cancer, melanoma, and renal cell carcinoma.1

Education and Training

Feltquate has a strong academic background in biology, medicine, and immunology:

B.S. in Biology from the Massachusetts Institute of Technology
M.D./Ph.D. (immunology) from University of Massachusetts Medical School
Completed internal medicine training at Dartmouth Hitchcock Medical Center
Completed medical oncology training at Memorial Sloan Kettering Cancer Center1 3

David Feltquate's career demonstrates a deep commitment to advancing cancer treatments, particularly in the fields of immuno-oncology and hematology. His expertise in clinical development and translational medicine has made him a valuable leader in the pharmaceutical industry.